73
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

Eutectic phase transition during tablet manufacture: effect of melting point of eutectic forming drug

, &
Pages 811-825 | Received 29 May 2023, Accepted 26 Sep 2023, Published online: 10 Oct 2023

References

  • Abdelkader H, Abdallah OY, Salem H, Alani AW, Alany RG. 2014. Eutectic, monotectic and immiscibility systems of nimesulide with water-soluble carriers: phase equilibria, solid-state characterisation and in-vivo/pharmacodynamic evaluation. J Pharm Pharmacol. 66(10):1439–1450. doi: 10.1111/jphp.12277.
  • Alladi S, Shastri NR. 2015. Semi solid matrix formulations of meloxicam and tenoxicam: an in vitro and in vivo evaluation. Arch Pharm Res. 38(5):801–812. doi: 10.1007/s12272-014-0396-3.
  • Alshaikh RA, Essa EA, El Maghraby GM. 2020. Preparation of stabilized submicron fenofibrate crystals on niacin as a hydrophilic hydrotropic carrier. Pharm Dev Technol. 25(2):168–177. doi: 10.1080/10837450.2019.1682609.
  • Alshaikh RA, Essa EA, El Maghraby GM. 2019. Eutexia for enhanced dissolution rate and anti-inflammatory activity of nonsteroidal anti-inflammatory agents: caffeine as a melting point modulator. Int J Pharm. 563:395–405. doi: 10.1016/j.ijpharm.2019.04.024.
  • Bhinge JR, Kumar RV, Sinha VR. 2008. A simple and sensitive stability-indicating RP-HPLC assay method for the determination of aceclofenac. J Chromatogr Sci. 46(5):440–444. doi: 10.1093/chromsci/46.5.440.
  • Bi M, Hwang SJ, Morris KR. 2003. Mechanism of eutectic formation upon compaction and its effects on tablet properties. Thermochim Acta. 404(1–2):213–226. doi: 10.1016/S0040-6031(03)00185-0.
  • Cherukuvada S, Nangia A. 2012. Fast dissolving eutectic compositions of two antitubercular drugs. CrystEngComm. 14(7):2579–2588. doi: 10.1039/c2ce06391c.
  • Clitherow KH, Murdoch C, Spain SG, Handler AM, Colley HE, Stie MB, Nielsen HM, Janfelt C, Hatton PV, Jacobsen J. 2019. Mucoadhesive electrospun patch delivery of lidocaine to the oral mucosa and investigation of spatial distribution in a tissue using MALDI-mass spectrometry imaging. Mol Pharm. 16(9):3948–3956. doi: 10.1021/acs.molpharmaceut.9b00535.
  • Dengale SJ, Grohganz H, Rades T, Löbmann K. 2016. Recent advances in co-amorphous drug formulations. Adv Drug Deliv Rev. 100:116–125. doi: 10.1016/j.addr.2015.12.009.
  • Dev S, Iyer KS, Raston CL. 2011. Nanosized drug formulations under microfluidic continuous flow. Lab Chip. 11(19):3214–3217. doi: 10.1039/c1lc20666d.
  • El Maghraby GM, Alomrani AH. 2009. Synergistic enhancement of itraconazole dissolution by ternary system formation with pluronic F68 and hydroxypropylmethylcellulose. Sci Pharm. 77(2):401–417. doi: 10.3797/scipharm.0901-08.
  • El-Gazayerly ON. 2000. Characterization and evaluation of tenoxicam coprecipitates. Drug Dev Ind Pharm. 26(9):925–930. doi: 10.1081/ddc-100101319.
  • Elkholy NE, Sultan AA, Elosaily GH, El Maghraby GM. 2020. Acetone-assisted co-processing of meloxicam with amino acids for enhanced dissolution rate. Pharm Dev Technol. 25(7):882–891. doi: 10.1080/10837450.2020.1755982.
  • Emami S, Siahi-Shadbad M, Adibkia K, Barzegar-Jalali M. 2018. Recent advances in improving oral drug bioavailability by cocrystals. Bioimpacts. 8(4):305–320. doi: 10.15171/bi.2018.33.
  • Figueiredo CBM, Nadvorny D, De Medeiros Vieira ACQ, Soares Sobrinho JL, Rolim Neto PJ, Lee PI, De La Roca Soares MF. 2017. Enhancement of dissolution rate through eutectic mixture and solid solution of posaconazole and benznidazole. Int J Pharm. 525(1):32–42. doi: 10.1016/j.ijpharm.2017.04.021.
  • Fitriani L, Firdaus WA, Sidadang W, Rosaini H, Putra OD, Oyama H, Uekusa H, Zaini E. 2022. Improved solubility and dissolution rate of ketoprofen by the formation of multicomponent crystals with tromethamine. Crystals. 12(2):275. doi: 10.3390/cryst12020275.
  • Fries AT, Olegário N, Campanharo SC, Pereira V, Steppe M. 2018. Evaluation of the presence of polymorphic forms and influence on the dissolution profile of tenoxicam in active pharmaceutical ingredient and formulations. Drug Anal Res. 2(2):27–36. doi: 10.22456/2527-2616.90005.
  • Gala U, Chuong MC, Varanasi R, Chauhan H. 2015. Characterization and comparison of lidocaine–tetracaine and lidocaine–camphor eutectic mixtures based on their crystallization and hydrogen-bonding abilities. AAPS PharmSciTech. 16(3):528–536. doi: 10.1208/s12249-014-0242-4.
  • Goldberg AH, Gibaldi M, Kanig JL, Mayersohn M. 1966. Increasing dissolution rates and gastrointestinal absorption of drugs via solid solutions and eutectic mixtures IV: chloramphenicol–urea system. J Pharm Sci. 55(6):581–583. doi: 10.1002/jps.2600550610.
  • Haneef J, Chadha R. 2017. Drug–drug multicomponent solid forms: cocrystal, co amorphous and eutectic of three poorly soluble antihypertensive drugs using mechanochemical approach. AAPS PharmSciTech. 18(6):2279–2290. doi: 10.1208/s12249-016-0701-1.
  • Hyun S, Joon B, Abuzar S, Lee S, Joo Y, Hong SH, Kang H, Kwon KA, Velaga S, Hwang SJ. 2019. Preparation, characterization, and evaluation of celecoxib eutectic mixtures with adipic acid/saccharin for improvement of wettability and dissolution rate. Int J Pharm. 554:61–71. doi: 10.1016/j.ijpharm.2018.10.044.
  • Iurian S, Dinte E, Iuga C, Bogdan C, Spiridon I, Barbu-Tudoran L, Bodoki A, Tomuţă I, Leucuţa SE. 2017. The pharmaceutical applications of a biopolymer isolated from Trigonella foenum-graecum seeds: focus on the freeze-dried matrix forming capacity. Saudi Pharm J. 25(8):1217–1225. doi: 10.1016/j.jsps.2017.09.006.
  • Khan KA. 1975. The concept of dissolution efficiency. J Pharm Pharmacol. 27(1):48–49. doi: 10.1111/j.2042-7158.1975.tb09378.x.
  • Manikkath J, Hegde AR, Kalthur G, Parekh HS, Mutalik S. 2017. Influence of peptide dendrimers and sonophoresis on the transdermal delivery of ketoprofen. Int J Pharm. 521(1–2):110–119. doi: 10.1016/j.ijpharm.2017.02.002.
  • Marei HF, Arafa MF, Essa EA, El Maghraby GM. 2021. Lidocaine as eutectic forming drug for enhanced transdermal delivery of nonsteroidal anti-inflammatory drugs. J Drug Deliv Sci Technol. 61:102338. doi: 10.1016/j.jddst.2021.102338.
  • Maulvi FA, Dalwadi SJ, Thakkar VT, Soni TG, Gohel MC, Gandhi TR. 2011. Improvement of dissolution rate of aceclofenac by solid dispersion technique. Powder Technol. 207(1–3):47–54. doi: 10.1016/j.powtec.2010.10.009.
  • Merisko EL. 2002. Nanocrystals: resolving pharmaceutical formulation issues associated with poorly water-soluble compounds. In: Marty JJ, editor. Particles. Orlando: Marcel Dekker.
  • Partheniadis I, Nikolakakis I, Zacharis CK, Kachrimanis K, Al-Zoubi N. 2021. Co-spray drying of paracetamol and propyphenazone with polymeric binders for enabling compaction and stability improvement in a combination tablet. Pharmaceutics. 13(8):1259. doi: 10.3390/pharmaceutics13081259.
  • Pomazi A, Ambrus R, Sipos P, Szabo-Revesz P. 2011. Analysis of co-spray-dried meloxicam-mannitol systems containing crystalline microcomposites. J Pharm Biomed Anal. 56(2):183–190. doi: 10.1016/j.jpba.2011.05.008.
  • Sakata Y, Tanabe E, Sumikawa T, Shiraishi S, Tokudome Y, Otsuka M. 2007. Effects of solid-state reaction between paracetamol and cloperastine hydrochloride on the pharmaceutical properties of their preparations. Int J Pharm. 335(1–2):12–19. doi: 10.1016/j.ijpharm.2006.10.038.
  • Thipparaboina R, Thumuri D, Chavan R, Naidu VGM, Shastri NR. 2017. Fast dissolving drug–drug eutectics with improved compressibility and synergistic effects. Eur J Pharm Sci. 104:82–89. doi: 10.1016/j.ejps.2017.03.042.
  • Vippagunta SR, Maul KA, Tallavajhala S, Grant DJW. 2002. Solid-state characterization of nifedipine solid dispersions. Int J Pharm. 236(1–2):111–123. doi: 10.1016/s0378-5173(02)00019-4.
  • Wahab A, Khan GM, Akhlaq M, Khan NR, Hussain A, Khan MF, Khan H. 2011. Formulation and evaluation of controlled release matrices of ketoprofen and influence of different co-excipients on the release mechanism. Pharmazie. 66:677–683.
  • Zalac S, Khan MZ, Gabelica V, Tudja M, Mestrović E, Romih M. 1999. Paracetamol–propyphenazone interaction and formulation difficulties associated with eutectic formation in combination solid dosage forms. Chem Pharm Bull (Tokyo). 47(3):302–307. doi: 10.1248/cpb.47.302.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.